Boston Scientific (NYSE:BSX) Announces Earnings Results, Beats Expectations By $0.03 EPS

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03, FiscalAI reports. Boston Scientific had a return on equity of 19.36% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $0.75 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific updated its Q3 2026 guidance to 0.800-0.820 EPS and its FY 2026 guidance to 3.280-3.320 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Second-quarter results exceeded guidance, with organic revenue growth of 7% and adjusted EPS of $0.86, up 15% year over year and above the $0.82–$0.84 forecast range.
• Boston Scientific reduced its 2026 outlook to 5%–6% organic revenue growth and adjusted EPS of $3.28–$3.32, citing sharper-than-expected pressure in U.S. electrophysiology and a slowdown in WATCHMAN adoption.
• WATCHMAN growth is expected to decline mid- to high-single digits globally in the second half, while EP growth is expected to be flat; management also anticipates limited EPS growth and margin pressure in 2027.
• A company-wide restructuring program is expected to generate approximately $500 million in annualized savings by the end of 2029, with more than half realized by the end of 2027 and reinvestment directed toward priority growth areas.
• Management highlighted strong momentum in interventional cardiology, neuromodulation, interventional oncology, and vascular therapies, alongside longer-term catalysts including Penumbra, coronary IVL, FARAWAVE Ultra, ICE imaging, and potential MiRus TAVR assets.

Boston Scientific Stock Down 2.7%

BSX stock traded down $1.23 during mid-day trading on Friday, reaching $44.77. 4,663,760 shares of the company traded hands, compared to its average volume of 18,278,361. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The firm’s 50 day moving average price is $46.35 and its 200 day moving average price is $62.37. The stock has a market cap of $66.55 billion, a price-to-earnings ratio of 18.12, a P/E/G ratio of 0.89 and a beta of 0.58. Boston Scientific has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on BSX shares. TD Cowen dropped their price target on Boston Scientific from $61.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday. Citigroup lowered their price objective on shares of Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $60.00 target price on shares of Boston Scientific in a research report on Thursday. Oppenheimer decreased their price target on shares of Boston Scientific from $90.00 to $85.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Truist Financial cut their price objective on shares of Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported second-quarter adjusted EPS of $0.86 and revenue of $5.44 billion, exceeding consensus estimates of $0.83 and approximately $5.38 billion. Revenue increased 7.5% year over year, supported by broad-based cardiovascular growth and margin expansion. Boston Scientific Q2 earnings report
• Positive Sentiment: Management highlighted cost-saving initiatives, new product catalysts and a multiyear restructuring program that could improve efficiency over time. Several analysts still rate BSX “buy,” with targets well above the current price, including UBS at $74, TD Cowen at $56 and Truist at $57.
• Neutral Sentiment: Penumbra (NYSE: PEN), which Boston Scientific is acquiring, reported second-quarter revenue growth of 14.9% to $390 million, including 12.5% growth in thrombectomy revenue. However, Penumbra will not provide full-year guidance because of the pending acquisition. Penumbra second-quarter results
• Negative Sentiment: Boston Scientific lowered its full-year 2026 adjusted EPS outlook to $3.28–$3.32 from $3.34–$3.41, citing weaker-than-expected demand and competitive pressure affecting the Watchman heart implant and electrophysiology portfolios. Boston Scientific guidance reduction
• Negative Sentiment: Recent price-target reductions from BTIG, UBS, TD Cowen and Truist reflect a more cautious outlook. The company also faces a product recall and restructuring costs of up to $800 million, adding near-term uncertainty despite the earnings beat.

Boston Scientific declared that its Board of Directors has authorized a stock buyback plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Insider Activity at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 9,800 shares of company stock valued at $554,012 over the last 90 days. Insiders own 0.34% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of BSX. Brighton Jones LLC increased its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific in the second quarter worth $26,000. Main Street Financial Solutions LLC increased its position in Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after buying an additional 1,971 shares during the last quarter. Ieq Capital LLC raised its stake in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after buying an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its position in shares of Boston Scientific by 56.2% during the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after buying an additional 2,556 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.